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Abstract
Background:  Angiogenesis assays are important tools for the identification of regulatory
molecules and the potential development of therapeutic strategies to modulate neovascularization.
Although numerous in vitro angiogenesis models have been developed in the past, they exhibit
limitations since they do not recapitulate the entire angiogenic process or correspond to multi-step
procedures that are not easy to use. Convenient, reliable, easily quantifiable and physiologically
relevant assays are still needed for pharmacological screenings of angiogenesis.
Results: Here, we have optimized an angiogenesis model based on ES cell differentiation for
screening experiments. We have established conditions leading to angiogenic sprouting of
embryoid bodies during ES cell differentiation in type I three-dimensional collagen gels.
Immunostaining experiments carried out during these cultures showed the formation of numerous
buds comprising CD31 positive cells, after 11 days of culture of ES cells. Moreover, this one-step
model has been validated in response to activators and inhibitors of angiogenesis. Sprouting was
specifically stimulated in the presence of VEGF and FGF2. Alternatively, endothelial sprouting
induced by angiogenic activators was inhibited by angiogenesis inhibitors such as angiostatin, TGFβ
and PF4. Sprouting angiogenesis can be easily quantified by image analysis after immunostaining of
endothelial cells with CD31 pan-endothelial marker.
Conclusion: Taken together, these data clearly validate that this one-step ES differentiation model
constitutes a simple and versatile angiogenesis system that should facilitate, in future investigations,
the screening of both activators and inhibitors of angiogenesis.
Background
Angiogenesis, the process of growth of blood capillaries
from the pre-existing vascular tree, is a complex phenom-
enon that is either associated with or involved in the
development of numerous physiological or pathological
situations [1,2]. Among them, angiogenesis is considered
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crucial for revascularization after cardiac ischemia, and is
also implicated in the pathogenesis of rheumatoid arthri-
tis, diabetic retinopathy, and tumoral progression. In par-
ticular, numerous clinical and experimental data show
that the growth of cancerous tumors and the formation of
metastases are highly dependent on the establishment of
tumoral neovascularization from the pre-existing vascular
network [3]. The tumor microvascular network then rep-
resents a new target for cancer treatment and the identifi-
cation and characterization of molecules that control the
formation of blood vessels become of interest in the
development of anti-cancer therapies. In addition, there is
also a great interest in combining antiangiogenic therapy
with other conventional cytotoxic therapies in cancer
treatment since several studies have demonstrated that the
delivery of therapeutics may be increased during vessel
normalization induced by angiostatics [2].
Several angiogenesis regulators have now been identified
and characterized [4]. Although first clinical trials of sin-
gle agent antiangiogenic treatment have not always given
satisfactory results, the use of an antiangiogenic therapy
still remains highly promising in pathologies where ang-
iogenesis is undesired [5]. In contrast, strategies aimed at
stimulating angiogenesis could also present interest in
many cases where neovascularization is needed such as
after cardiac ischemia or after tissue graft. Then, there is a
great challenge to find new potential angiogenesis activa-
tors or inhibitors that may be candidate for therapeutics.
Within this context, the setting up of models for screening
active molecules (angioactive or angiostatic) on the ang-
iogenic response, is of considerable importance. Numer-
ous in vitro angiogenesis models have been developed
[6,7]. They are either two-dimensional (2D) models such
as conventional cell proliferation and migration tests or
more elaborated three-dimensional (3D) assays. Con-
cerning 3D angiogenesis models, assays involving
Matrigel, a matrix derived from mouse Engelbreth-Holm-
Swarm sarcoma, are among the most common commer-
cially available in vitro angiogenesis assays. Other 3D
models are based on the use of fibrin or type-1 collagen as
a support matrix for endothelial cells. However, both 2D
and 3D models mostly involve the study of one particular
step of the angiogenic response, but do not recapitulate
the entire angiogenic process including proliferation,
migration and tubulogenesis. Although they exhibit some
interest for primary screening because of their simplicity,
an assay recapitulating all the sprouting angiogenic proc-
ess should be preferable since it would be more physio-
logically relevant. Other models that more closely
recapitulate the sprouting angiogenic response have there-
fore been established. They include models based on the
3D culture of endothelial cell-coated microcarriers or
endothelial cell spheroids embedded in collagen gels
[8,9]. However, they require multi-step procedures and
are not easy to perform. Mouse embryonic stem cells (ES
cells) have also been shown to be a good alternative as a
system for the study of differentiation towards the
endothelial lineage [10-14]. In addition, this cellular sys-
tem, into which genetic modifications can easily be intro-
duced, can go through most of the stages of budding
angiogenesis as observed in vivo [15-17]. In the previ-
ously described ES cell model, two steps are required for
angiogenesis to proceed [15]. First, ES cells are induced to
differentiate into embryoid bodies (EBs). EBs are then col-
lected and further cultured into a type I 3D collagen
matrix for another period, during which the EB primary
vascular structures extend and invade the collagen matrix,
leading to complex and ramified endothelial sprouts
mimicking the sprouting angiogenesis process. This two-
step model makes possible to carry out qualitative and
quantitative studies by cell imaging [15]. All of these char-
acteristics together, therefore, make it a powerful study
model that enables to evaluate, in vitro, the efficiency of
active molecules with respect to both vascular develop-
ment and angiogenesis, and to improve the understand-
ing of the molecular mechanisms that are called into play
during these responses.
Ideally, an in vitro angiogenesis assay suitable for the
screening of potentially active compounds should be con-
venient, reliable, easily quantifiable and physiologically
relevant. In addition, it should allow evaluation of multi-
ple samples in one experiment. Although the ES cell-
based angiogenesis model fills most of these require-
ments, it remains time consuming since it proceeds in two
culture steps and requires many manual interventions
before being processed for angiogenesis visualization and
quantification that may constitute an inconvenient for
screening experiments.
Matrix proteins, including type I collagen, support cell dif-
ferentiation in many lineages [18]. A recent study indi-
cated that ES cells can undergo multi-lineage
differentiation including differentiation into cells of the
endothelial lineage when plated directly into collagen gels
[19]. A 3D collagen environment for ES cell differentia-
tion then appears to constitute a mean to improve ES two-
step angiogenesis models. Moreover, some early unpub-
lished data have also postulated that ES cell differentia-
tion into a mixture of type I and type III collagens could
be used for the screening of angiogenesis regulating fac-
tors [20]. In this context, the aim of the present work was
to simplify the in vitro differentiation model of ES cells in
order to establish and to validate a one-step model that
may be relevant for the preclinical screening of active mol-
ecules on angiogenesis.BMC Biotechnology 2007, 7:20 http://www.biomedcentral.com/1472-6750/7/20
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Results
In order to simplify the two step ES-based angiogenesis
initial model, a first series of experiments was designed to
test the ability of type I collagen to support the formation
of EBs and of endothelial sprouts. A type I collagen gel was
used since previous works have shown that sprouting ang-
iogenesis can develop from EBs embedded in this matrix
[15,16,21], and since type I collagen was observed to sup-
port multilineage ES cell differentiation [19]. ES cells were
directly seeded into type I collagen gels in the presence of
angiogenic factors (50 ng/ml VEGF and 100 ng/ml FGF2)
in 35 mm-diameter dishes or in 12-well microplate for-
mat (Figure 1A). VEGF was added since it has been proven
efficient for both ES cell endothelial differentiation
[12,22,23] and ES-derived EB sprouting angiogenesis
[15]. In addition to the regulation of the early stages of
mesoderm induction and angioblast formation [24],
FGF2 was also shown to increase vascular development in
the embryoid body model [12,25,26]. In these condi-
tions, formation of EBs was observed within a few days, as
previously described in methylcellulose semi-solid differ-
entiation medium [15,16]. First signs of EB sprouting
were observed after day 6 of differentiation. These sprouts
further extended and developed a complex cellular net-
work after 11 days of differentiation. CD31 immunostain-
ing experiments revealed that many sprouts were
constituted of endothelial cells. EBs exhibiting CD31-pos-
itive sprouts were termed angiogenic. In the presence of
both VEGF and FGF2, added at the initiation of the cul-
ture, near 30% of EBs (31.1 ± 19.3%, SD, n = 5) displayed
an angiogenic phenotype, whereas less than 5% of EBs
(4.8 ± 3.6%, SD, n = 2) were found angiogenic when no
exogenous growth factor addition was done (Figure 1B).
To improve the number of angiogenic EBs, repeated addi-
tion of angiogenic factors were tested during the course of
ES cell differentiation in collagen gels. We have found that
a second growth factor addition at day 6 of differentiation
greatly improved the development of angiogenic EBs to a
level similar to that observed in the initial two-step model
[15]. In this condition, 80 to 100 EBs (88 ± 28, SD, n = 19)
can form from 2,000 ES cells when initially plated in 35
mm-diameter dishes, and we observed that more than
60% of EBs (64.9 ± 7%, SD, n = 25) displayed a sprouting
angiogenic phenotype when two growth factor additions
were performed (Figure 1B). A representative sprouting
angiogenic EB is illustrated in Figure 1C.
In order to characterize the maturation level that can be
achieved in endothelial sprouts, we then looked at vWF
expression, a marker characteristic of mature endothelial
cells, and investigated whether pericytes may be associ-
ated with endothelial sprouts by looking at the expression
of NG2 proteoglycan. NG2 proteoglycan has been shown
to be expressed by nascent pericytes during development
[27]. Such an association between endothelial cells and
vascular mural cells was previously described in two steps
more complex ES cell-based differentiation models
[22,15,21]. We observed that several cells located in the
CD31-positive sprouts contained vWF, as shown by co-
immunofluorescence studies (Figure 2, upper panels).
Analysis of EB sprouts also revealed that several NG2 pro-
teoglycan-positive cells can be found in the vicinity of the
endothelial cells constituting the sprouts (Figure 2, lower
panels).
To validate the one-step model as a screening assay for
both activators and inhibitors of angiogenesis, we exam-
ined whether known angiogenesis regulators were able to
affect the sprouting response. After CD31 immunostain-
ings, EBs exhibiting endothelial CD31-positive sprouts
were selected for image capture. In each experiment, at
least 15 different EBs and in most cases more than 24 EBs
were analyzed per condition of test. The extent of the EB
endothelial sprouting was quantified by morphometric
analysis using the MetaMorph software. Figure 3 illus-
trates the result of the image processing with the Meta-
Morph software. We first analyzed the respective
contribution of VEGF and of FGF2 on the EB endothelial
sprouting response. For this experimental series, ES cell
differentiation was initiated in the presence of both VEGF
and FGF2 added at day 0. The EB endothelial sprouting
responses induced by the addition at day 6 of optimal
VEGF and FGF2 concentrations [15], used alone or in
combination, were quantified at day 11. We found that
VEGF plays a key role in the formation of endothelial
sprouts since its addition was responsible for approxi-
mately 60% of the EB endothelial sprouting response
obtained when both VEGF and FGF2 were present (Figure
4). The contribution of FGF2 was lower than that of VEGF,
and the effects of the two factors were found to be additive
(Figure 4).
We also evaluated whether agents exhibiting known
antiangiogenic activity were effective in this system. Sev-
eral angiogenesis inhibitors are now identified and char-
acterized including matrix-derived and non-matrix-
derived compounds [28]. Among these two categories,
Platelet Factor 4 (PF4), angiostatin (kringle1–4) and
Transforming Growth Factor β1 (TGFβ) were tested on the
endothelial sprouting response induced by angiogenic
factors (50 ng/ml VEGF and 100 ng/ml FGF2). Quantita-
tive analysis revealed that 2.5 μg/ml PF4 decreased the
length of endothelial sprouts. Moreover, treatment with
2.5 μg/ml angiostatin or with 10 ng/ml TGFβ resulted in
highly significant inhibition of the mean length of total
endothelial sprouts per EB (Figure 5).
Discussion
In this paper, we report the development and the valida-
tion of a simple one-step ES cell differentiation model forBMC Biotechnology 2007, 7:20 http://www.biomedcentral.com/1472-6750/7/20
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Development of angiogenic embryoid bodies during one-step ES cell differentiation into type I collagen gels Figure 1
Development of angiogenic embryoid bodies during one-step ES cell differentiation into type I collagen gels. A, 
Schematic illustration of the one-step method, performed either in 35 mm-diameter plates or in 12-well microplates, com-
pared with the two-step initial angiogenesis model; B, Effect of the addition of angiogenic growth factors (VEGF + FGF2) on the 
formation of EBs exhibiting endothelial sprouts (angiogenic EBs). ES cell differentiation was performed in the absence (0) or in 
the presence (1) of angiogenic growth factors added at the initiation of the differentiation of CJ7 ES cells at day 0. (1+2), effect 
of a second angiogenic growth factor addition at day 6, in addition to day 0, on the formation of sprouting angiogenic EBs. *** 
p < 0.001; mean values significantly different by unpaired Student's t test. C, CD31 immunostaining of a 11 day-old angiogenic 
embryoid body derived from CJ7 ES cells obtained in the one-step differentiation method. The arrow points to a CD31-posi-
tive endothelial sprout (red staining) and arrowheads to CD31-negative sprouts that only exhibit blue staining of cell nuclei 
after Hoescht 33258 counterstaining. Scale bar = 200 μm.BMC Biotechnology 2007, 7:20 http://www.biomedcentral.com/1472-6750/7/20
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the screening of angiogenesis regulators. We provide evi-
dence that this one-step model can recapitulate the vari-
ous stages of sprouting angiogenesis, as initially reported
for previously established two-step ES differentiation
models. Moreover, we describe a standardized procedure
to obtain reproducible and efficient development of
endothelial sprouts from EBs using this one-step model.
Compared with the two-step procedure, only one growth
factor addition is required after initial seeding without
any further intervention, which greatly simplifies the test.
In comparison with other available in vitro models, the
one-step ES cell based angiogenesis model shows the
major advantage of reproducing at least three aspects of
the sprouting angiogenesis response: proliferation, migra-
tion and vascular morphogenesis. As previously observed
in two-step ES cell differentiation procedures [22,15,21],
the vascular endothelial sprouts that develop in the one-
step ES cell model are associated with pericytes, which
confers to the one-step model superiority to many in vitro
angiogenesis models that mostly recapitulate only limited
aspects of the angiogenic response [7].
Multiple steps of the angiogenic process may be altered by
an angiogenesis-targeted drug. The fact that the ES differ-
entiation model mimicks the complexity of the sprouting
angiogenesis response makes it relevant for further identi-
fication of novel molecules and mechanisms regulating
this process. EB endothelial sprouting was specifically
induced by angioactive molecules, namely VEGF and to a
minor extent FGF2, and inhibited by known angiostatic
factors. These data validate the one-step ES differentiation
model as a versatile angiogenesis system for the screening
of both activators and inhibitors of angiogenesis.
The ES differentiation one-step procedure is easier to use
than the other 3D angiogenesis existing models since they
all proceed into two steps and require extensive manipu-
lations. Screening experiments can be performed in both
6-well or 12-well-microplaque format that could be very
useful for further adaptation of the model for automatiza-
tion and may be convenient to further characterize mole-
cules identified by primary screens using less complete
cellular models.
Double immunostainings of embryoid bodies sprouts for CD31, von Willebrand factor (vWF) and NG2 proteoglycan Figure 2
Double immunostainings of embryoid bodies sprouts for CD31, von Willebrand factor (vWF) and NG2 prote-
oglycan. CJ7 ES cells were allowed to differentiate in the presence of angiogenic growth factors (VEGF+FGF2) added at day 0. 
EBs angiogenic sprouts were analyzed at day 11 of differentiation. vWF immunoreactivity (red fluorescence) located in Weibel-
Palade bodies can be observed in several sprouting CD31-positive cells (green fluorescence) (upper panels). Elongated NG2 
proteoglycan-positive cells (red fluorescence) can be seen close to CD31-positive cells constituting endothelial sprouts (lower 
panels). Scale bar = 50 μm.BMC Biotechnology 2007, 7:20 http://www.biomedcentral.com/1472-6750/7/20
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Conclusion
Thus, the one-step ES-based angiogenesis model, that
allows routine and reproducible accomplishment in a
reduced time, constitutes a good alternative for existing in
vitro angiogenesis models. In addition, in view of its sim-
plicity, it allows an easy transfer to non-specialist investi-
gators. We expect the one-step ES angiogenesis model to
be particularly valuable to extend drug discovery screen-
ing.
Methods
Embryonic Stem (ES) cell differentiation
CJ7-ES cells [29], and on rare occasions R1-ES cells [30],
were used. ES cells were cultured on gelatin-coated cell
culture dishes and were maintained undifferentiated in
the presence of 103 U/ml Leukemia Inhibitory Factor (LIF)
(ESGRO, Chemicon, Temecula, CA) as previously
described [12]. At day 0, to initiate the differentiation,
cells were collected by trypsin, counted and resuspended
in Iscove modified Dulbecco's medium (IMDM), before
being gently mixed into a type I collagen-medium in the
presence of angiogenic factors: 50 ng/ml VEGF (Pepro-
tech, Rocky Hill, NJ) and 100 ng/ml FGF2(a generous gift
from Dr Ana Maria Gonzales, Queen Elizabeth medical
Quantitative analysis of endothelial sprouting in response to  FGF2 and VEGF Figure 4
Quantitative analysis of endothelial sprouting in 
response to FGF2 and VEGF. CJ7 ES cells were first 
induced to differentiate at day 0 in the presence of both 
VEGF (50 ng/ml) and FGF2 (100 ng/ml). For the second 
growth factor addition at day 6, VEGF (50 ng/ml) and FGF2 
(100 ng/ml) were added alone or in combination. The mean 
total sprout length of EBs exhibiting endothelial sprouts (ang-
iogenic EBs) was measured at day 11, after CD31 immunos-
taining, and image analysis with MetaMorph Offline software. 
Data represent the mean values ± SD resulting from at least 
25 angiogenic EBs obtained in one differentiation experiment.
Image processing for quantitation of endothelial sprouting  using MetaMorph Offline software Figure 3
Image processing for quantitation of endothelial 
sprouting using MetaMorph Offline software. A, Initial 
image of the CD31 staining of an 11-day-old angiogenic EB 
derived from CJ7 ES cells; B, Skeletonized image of image A; 
C, Superposition of image B and image A. Scale bar = 400 
μm.BMC Biotechnology 2007, 7:20 http://www.biomedcentral.com/1472-6750/7/20
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center, Birmingham, UK). Final composition of the colla-
gen-medium was 15% fetal calf serum (FCS) (Biowest,
Nuaillé, France), 450 μM of monothioglycerol, 1.2 mg/ml
type I collagen (BD Biosciences, Bedford, MA) neutralized
with 1 N NaOH (according to the manufacturer recom-
mendation), 10 μg/ml insulin and 0.5% penicillin-strep-
tomycin. Practically, final ES cell suspensions in the
collagen medium were obtained by mixing ES cells in col-
lagen solution with a concentrated solution of medium as
previously detailed in the procedure for EB secondary cul-
ture into type I collagen gels [31]. ES cells in collagen-
medium were poured either in 35-mm bacterial dishes
(1.5 ml per well) or in 12-well bacterial microplaque (1
ml per well) at a concentration of 2,000 cells/well, leading
to the obtention of a 1.5 mm-thick or a 2.4 mm-thick gel,
respectively. The cells were incubated at 37°C, in a 5%
CO2, 95% air atmosphere. At day 6, a second addition of
VEGF and FGF2 was done using the same concentrations
of growth factors as used at day 0. Factors were diluted
either into 100 μl or into 200 μl medium lacking collagen
before being added to 12-well plates or 35-mm dishes,
respectively. Cultures were stopped at day 11 for EBs anal-
ysis.
Immunofluorescence
At day 11 of differentiation, collagen gels containing EBs
were collected on glass slides. Dehydration was obtained
using nylon linen and adsorbent cards, thus allowing 2D
projection of the sprouts. EBs were then fixed using 3%
paraformaldehyde in PBS for 15 minutes at room temper-
ature. After three washes with PBS, slides were incubated
1 hour at room temperature with rat anti-mouse CD31
monoclonal antibody MEC-13.3 [32], (a generous gift
from Dr A. Vecchi, Mario Negri Institute, Milan, Italy),
used as undiluted hybridoma supernatant. After 3 rinses,
slides were incubated for one hour at room temperature
with cyanine 3-conjugated goat anti-rat IgG (Jackson
Immunoresearch Laboratories, West Grove, PA) diluted
Quantitative analysis of endothelial sprouting in response to angiogenesis inhibitors Figure 5
Quantitative analysis of endothelial sprouting in response to angiogenesis inhibitors. For inhibition studies of EB 
endothelial sprouting, VEGF (50 ng/ml) and FGF2 (100 ng/ml) were added at day 0 and at day 6 as indicated in the Methods. At 
day 6, EBs were also treated by the indicated angiogenesis inhibitors or by their respective vehicle (VHL). Analysis of the mean 
total sprout length of angiogenic EBs was performed at day 11 on 39, 25, 26, 18, 55 and 76 EBs treated with VHL TGFβ, 10 ng/
ml TGFβ, VHL PF4, 2.5 μg/ml PF4, VHL angiostatin and 2.5 μg/ml angiostatin, respectively. In each condition, data represent 
the mean values ± SE from one out of two differentiation experiments performed in collagen gel with CJ7 ES cells. * p < 0.05, 
*** p < 0.001; significantly different from respective control values by unpaired Student's t test.BMC Biotechnology 2007, 7:20 http://www.biomedcentral.com/1472-6750/7/20
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1:300. After three further washes in PBS, slides were coun-
terstained with Hoescht 33258. Slides were mounted in
Fluorsave (Calbiochem, La Jolla, CA).
In some experiments, EBs were double labeled with rat
anti-mouse CD31 monoclonal antibody MEC13.3, used
as undiluted hybridoma supernatant, and rabbit antibod-
ies directed against rat proteoglycan NG2 (1 μg/ml) (a
generous gift from Dr W.B. Stallcup, La Jolla, CA) or
against human von Willebrand factor (vWF) (DakoCyto-
mation, Trappes, France) (dilution 1:500), and the stain-
ing was revealed by incubation with a mixture of cyanine
3-conjugated goat anti-rabbit IgG (Jackson Immunore-
search Laboratories) and of Alexa488-conjugated goat
anti-rat IgG (Molecular Probes, Eugene, OR). When
immunofluorescence experiments were performed with
vWF antibodies, EBs were fixed and permeabilized with
3% paraformaldehyde and 0.5% Triton X-100 for 3 min,
followed by a supplementary 15 min fixation with 3%
paraformaldehyde alone, before rinses with PBS and
immunostainings.
Angiogenesis Inhibitors
When tested, angiogenesis inhibitors were added at day 6
at the same time of the second angiogenesis activators
addition. They were used at optimal concentrations
known to affect endothelial sprouting from EBs in the
two-step ES cell angiogenesis model [15,33]. Platelet fac-
tor 4 (PF4) (Diagnostica Stago, Asnières, france) was used
at 2.5 μg/ml; angiostatin (fragment K1–4) (Calbiochem)
was used at 2.5 μg/ml and Transforming Growth factor β1
(TGFβ) (R&D Systems, Abingdon, UK) was used at 10 ng/
ml. Inhibitors were added with angiogenesis growth fac-
tor activators (VEGF and FGF2) diluted in differentiation
medium to each well (100 μl) or dishes (200 μl).
Image analysis
After dehydration of the collagen gels to allow the com-
plete 2D projection of the sprouts and immunostaining
with anti-CD31 antibodies, the slides were observed using
a Zeiss Axioplan fluorescence microscope (Zeiss, Oberko-
chen, Germany). Images were captured, at 5× or at 10×
magnification, depending on the size of the sprouting
EBs, with a computer-supported digital Spot RT camera
using Spot advanced software (Diagnostic instruments,
Sterling Heights, MI). In order to quantify the sprouting,
images were processed for morphometric analysis using
Metamorph Offline software (Molecular Devices, Down-
ingtown, PA). A macrocommand was edited to give the
total endothelial sprout length of each EB after binariza-
tion and skeletonization of the image of the CD31 stain-
ing.
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